NEW YORK, April 8, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Encana Corporation (NYSE: ECA), Perrigo Company PLC (NYSE: PRGO), The Boeing Company (NYSE: BA), Genworth Financial Inc. (NYSE: GNW), and Itau Unibanco Holding SA (NYSE: ITUB). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Encana Corporation Analyst Notes
On March 31, 2014, Encana Corporation (Encana) disclosed that its wholly-owned subsidiary, Encana Oil & Gas (USA) Inc., has arrived at an agreement with an affiliate of TPG Capital (TPG) to sell certain natural gas properties in the Jonah field located in Sublette County, Wyoming, for a purchase price of about $1.8 billion. According to the Company, the transaction also includes over 100,000 undeveloped acres adjacent to Jonah known as the Normally Pressured Lance area. As stated, Encana's Jonah assets sale is expected to close in Q2 2014 with an effective date of December 1, 2013. Commenting on the development, Doug Suttles, Encana President & CEO said, "This transaction is consistent with our strategy. With the divestment of Jonah, we are unlocking value from a mature, high-quality asset and allowing our teams to focus on our five core growth areas and continue with execution of our new strategy." The full analyst notes on Encana Corporation are available to download free of charge at:
http://www.AnalystsReview.com/04082014/ECA/report.pdf
--
Perrigo Company PLC Analyst Notes
On April 1, 2014, Perrigo Company (Perrigo) introduced a new product under its umbrella and made its first shipments of the authorized generic version of LEO Pharma A/S' Taclonex® Ointment (calcipotriene 0.005% / betamethasone dipropionate 0.064%). Taclonex® Ointment is suggested for the treatment of plaque psoriasis of the scalp and body in patients, of 18 years and above. As stated, the brand sales amounted to nearly $110 million over the last 52 weeks. In relation with the Company's latest product launch, Joseph C. Papa, Chairman, President and CEO said, "This product was the result of the continued hard work and dedication of our Perrigo Rx team. This launch is another example of Perrigo's investment and commitment to making quality healthcare more affordable for consumers." The full analyst notes on Perrigo Company PLC are available to download free of charge at:
http://www.AnalystsReview.com/04082014/PRGO/report.pdf
--
The Boeing Company Analyst Notes
On April 3, 2014, Boeing Company (Boeing) reported its deliveries across the commercial and defense operations for Q1 2014 (period ended March 31, 2014). As reported by the Company, a total of 161 deliveries were made under the commercial airplanes programs, of which 737 Next Generation airplanes accounted for 115 deliveries in the quarter. According to the Company, 24 deliveries of 777 were made, making it the second highest delivered airplane, whereas no deliveries were reported for 767 during the same time period. According to the release, under the Defense, Space and Security Programs, 17 Chinook (New Builds) and 11 F/A-18E/F and EA-18G were delivered. The full analyst notes on The Boeing Company are available to download free of charge at:
http://www.AnalystsReview.com/04082014/BA/report.pdf
--
Genworth Financial Inc. Analyst Notes
On March 25, 2014, Genworth Financial Inc. (Genworth) issued a press release disseminating the reading for the Genworth Homebuyer Confidence Index, which declined to 90.8 points in March 2014 from 92.4 points in September 2013. The Company attributed the decline to a fall in confidence in the first homebuyer segment and cost of living pressures for mortgage holders. According to Genworth, the first homebuyers' component has fallen from 85.0 in September 2013 to 82.3 in March 2014, mainly led by concerns around underemployment. Confirming the decline in the Homebuyer Confidence Index, Bridget Sakr, Chief Commercial Officer of Genworth Australia said, "The marginal decline in confidence was driven largely by homebuyers experiencing or expecting mortgage stress." In addition, the proportion of those surveyed that thought that now was a good time to buy a home weakened from 46% in September 2013 to 42% in March 2014. The full analyst notes on Genworth Financial Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04082014/GNW/report.pdf
--
Itau Unibanco Holding SA Analyst Notes
On April 3, 2014, shares in Itau Unibanco Holding S.A. (Itau Unibanco) fell 1.88% to end the trading session at $15.17. The stock opened the session at $15.38, and traded in the range of $15.04 - $15.38, with a total of 14.10 million shares changing hands during the day. On April 1, 2014, a news article on Reuters reported that the U.S. investment firm Cartica Management LLC ("Cartica") has filed a lawsuit in New York against Chilean bank CorpBanca SA, its controlling shareholder, Ãlvaro Saieh, and his investment holding company over a plan to merge with Brazil's Itaú Unibanco Holding Financeira SA. The merger was announced on January 29, 2014, and the share price of Itau Unibancoahs has increased 26.95% since then. As per the news article, Cartica has alleged that the deal with Itau Unibanco, undervalues CorpBanca's shares, so as to give special benefits to Saieh, a Chilean billionaire, and his company CorpGroup. The full analyst notes on Itau Unibanco Holding SA are available to download free of charge at:
http://www.AnalystsReview.com/04082014/ITUB/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
